The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EPRX | +172.13% | N/A | N/A | +183% |
| S&P | +15.49% | +82.14% | +12.74% | +58% |
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell and John Salvatore Montalbano on May 12, 2011 and is headquartered in Victoria, Canada.
No news articles found for Eupraxia Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$62.99K | -66.8% |
| Market Cap | $212.16M | 126.5% |
| Net Income | -$6,369.36K | -6.3% |
| EBITDA | -$6,820.11K | -9.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $88.96M | 927.0% |
| Accounts Receivable | $13.57K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $94.47K | 560.7% |
| Short Term Debt | $76.14K | -3.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -57.20% | 0.0% |
| Return On Invested Capital | -304.10% | -23.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,591.90K | 55.1% |
| Operating Free Cash Flow | -$4,531.62K | 55.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 11.86 | 68.78 | -66.57 | -23.19 | -467.08% |
| Price to Tangible Book Value | 11.86 | 68.78 | -66.58 | -23.19 | -467.06% |
| Enterprise Value to EBITDA | -14.66 | -16.85 | -26.40 | -23.30 | 73.97% |
| Return on Equity | -108.9% | -154.9% | -59.0% | - | |
| Total Debt | $71.86K | $52.77K | $35.07K | $170.60K | 83.35% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
